Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials

Overview

Journal J Clin Med

Specialty General Medicine

Date 2021 Nov 27

PMID 34830648

Citations 5

Authors

Dimitrios Sagris

Matilda Florentin

Panagiotis Tasoudis

Eleni Korompoki

Nikolaos Gatselis

Evangelos J Giamarellos-Bourboulis

Haralampos Milionis

James Douketis

Alex C Spyropoulos

George Dalekos

George Ntaios

Affiliations

Soon will be listed here.

Abstract

Background: We aimed to investigate the potential beneficial effect of immunomodulation therapy on the thromboembolic risk in hospitalized COVID-19 patients.

Methods: We searched PubMed and Scopus for randomized trials reporting the outcomes of venous thromboembolism (VTE), ischemic stroke or systemic embolism, myocardial infarction, any thromboembolic event, and all-cause mortality in COVID-19 patients treated with immunomodulatory agents. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using the Mantel-Haenszel random effects method.

Results: Among 8499 patients hospitalized with COVID-19, 4638 were treated with an immunomodulatory agent, 3861-with usual care only. Among the patients prescribed immunomodulatory agents, there were 1.77 VTEs per 100 patient-months compared to 2.30 among those treated with usual care (OR: 0.84, 95% CI: 0.61-1.16; I: 0%). Among the patients who received an interleukin 6 (IL-6) antagonist, VTEs were reported in 12 among the 1075 patients compared to 20 among the 848 receiving the usual care (OR: 0.52, 95% CI: 0.22-1.20; I: 6%). Immunomodulators as an add-on to usual care did not reduce the risk of stroke or systemic embolism (OR: 1.10, 95% CI: 0.50-2.40; I: 0%) or of myocardial infarction (OR: 1.06, 95% CI: 0.47-2.39; I: 0%) and there was a nonsignificant reduction in any thromboembolic event (OR: 0.86, 95% CI: 0.65-1.14; I: 0%).

Conclusions: We did not identify a statistically significant effect of immunomodulation on prevention of thromboembolic events in COVID-19. However, given the large effect estimate for VTE prevention, especially in the patients treated with IL-6 antagonists, we cannot exclude a potential effect of immunomodulation.

Citing Articles

Impact of SARS-CoV-2 infection therapies on the risk of venous thromboembolism and cardiovascular events from the SEMI-COVID-19 Registry.

Oblitas C, Demelo-Rodriguez P, Barrera-Lopez L, Galeano-Valle F, Rubio-Rivas M, Luque Del Pino J Sci Rep. 2025; 15(1):7722.

PMID: 40044746 PMC: 11882944. DOI: 10.1038/s41598-025-90278-8.

The association between tocilizumab therapy and the development of thrombosis in critically ill patients with COVID-19: a multicenter, cohort study.

Aljuhani O, Al Sulaiman K, Korayem G, Altebainawi A, Alsohimi S, Alqahtani R Sci Rep. 2024; 14(1):3037.

PMID: 38321099 PMC: 10847412. DOI: 10.1038/s41598-024-53087-z.

Thromboembolic Presentations among Patients Hospitalized to the Intensive Care Unit for Coronavirus Disease 2019 (COVID-19) - A Northern Taiwan Single Center Experience.

Chen Y, Chen C, Wang A, Hou S, Lai K, Chou C Acta Cardiol Sin. 2023; 39(5):695-708.

PMID: 37720401 PMC: 10499957. DOI: 10.6515/ACS.202309_39(5).20230203A.

A Literature Review of Pathophysiology, Clinical Manifestations, Medications and Optimal Dosage, Outpatient, and Post-hospitalization Use of Anticoagulation in COVID-19 Patients.

Velissaris D, Michailides C, Karalis I, Paraskevas T, Koniari I, Pierrakos C Anatol J Cardiol. 2023; 27(5):232-239.

PMID: 37119193 PMC: 10160838. DOI: 10.14744/AnatolJCardiol.2023.3023.

Severe Digital Ischemia Associated with Upper Limb Arterial Thrombosis and Raynaud's Phenomenon in a Patient with Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Chen Y, Huang C, Lin T, Huang C Acta Cardiol Sin. 2022; 38(5):650-652.

PMID: 36176367 PMC: 9479058. DOI: 10.6515/ACS.202209_38(5).20220330D.

References

Dalekos G, Stefos A, Georgiadou S, Lygoura V, Michail A, Ntaios G . Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19. Eur J Intern Med. 2021; 88:52-62. PMC: 7997723. DOI: 10.1016/j.ejim.2021.03.026. View

Aziz M, Haghbin H, Sitta E, Nawras Y, Fatima R, Sharma S . Efficacy of tocilizumab in COVID-19: A systematic review and meta-analysis. J Med Virol. 2020; 93(3):1620-1630. DOI: 10.1002/jmv.26509. View

Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B . ST-Segment Elevation in Patients with Covid-19 - A Case Series. N Engl J Med. 2020; 382(25):2478-2480. PMC: 7182015. DOI: 10.1056/NEJMc2009020. View

Tomazini B, Maia I, Cavalcanti A, Berwanger O, Rosa R, Veiga V . Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020; 324(13):1307-1316. PMC: 7489411. DOI: 10.1001/jama.2020.17021. View

Angus D, Buzgau A, Cheng A, Higgins A, Hullegie S, Lawler P . Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020; 324(13):1317-1329. PMC: 7489418. DOI: 10.1001/jama.2020.17022. View

Narain S, Stefanov D, Chau A, Weber A, Marder G, Kaplan B . Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm. Chest. 2020; 159(3):933-948. PMC: 7567703. DOI: 10.1016/j.chest.2020.09.275. View

Chi G, Lee J, Jamil A, Gunnam V, Najafi H, Memar Montazerin S . Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis. J Clin Med. 2020; 9(8). PMC: 7463975. DOI: 10.3390/jcm9082489. View

Ridker P, Everett B, Thuren T, MacFadyen J, Chang W, Ballantyne C . Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; 377(12):1119-1131. DOI: 10.1056/NEJMoa1707914. View

Pontali E, Volpi S, Signori A, Antonucci G, Castellaneta M, Buzzi D . Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. J Allergy Clin Immunol. 2021; 147(4):1217-1225. PMC: 7865089. DOI: 10.1016/j.jaci.2021.01.024. View

10.

Ridker P, Devalaraja M, Baeres F, Engelmann M, Hovingh G, Ivkovic M . IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021; 397(10289):2060-2069. DOI: 10.1016/S0140-6736(21)00520-1. View

11.

Dequin P, Heming N, Meziani F, Plantefeve G, Voiriot G, Badie J . Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(13):1298-1306. PMC: 7489432. DOI: 10.1001/jama.2020.16761. View

12.

Pasin L, Cavalli G, Navalesi P, Sella N, Landoni G, Yavorovskiy A . Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies. Eur J Intern Med. 2021; 86:34-40. PMC: 7862887. DOI: 10.1016/j.ejim.2021.01.016. View

13.

Dubee V, Roy P, Vielle B, Parot-Schinkel E, Blanchet O, Darsonval A . Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial. Clin Microbiol Infect. 2021; 27(8):1124-1130. PMC: 8015393. DOI: 10.1016/j.cmi.2021.03.005. View

14.

Rosell A, Havervall S, von Meijenfeldt F, Hisada Y, Aguilera K, Grover S . Patients With COVID-19 Have Elevated Levels of Circulating Extracellular Vesicle Tissue Factor Activity That Is Associated With Severity and Mortality-Brief Report. Arterioscler Thromb Vasc Biol. 2020; 41(2):878-882. PMC: 7837685. DOI: 10.1161/ATVBAHA.120.315547. View

15.

Gordon A, Mouncey P, Al-Beidh F, Rowan K, Nichol A, Arabi Y . Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 384(16):1491-1502. PMC: 7953461. DOI: 10.1056/NEJMoa2100433. View

16.

. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021; 9(3):295-304. PMC: 7825875. DOI: 10.1016/S2213-2600(20)30556-7. View

17.

Gencer S, Lacy M, Atzler D, van der Vorst E, Doring Y, Weber C . Immunoinflammatory, Thrombohaemostatic, and Cardiovascular Mechanisms in COVID-19. Thromb Haemost. 2020; 120(12):1629-1641. PMC: 7869061. DOI: 10.1055/s-0040-1718735. View

18.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151(4):264-9, W64. DOI: 10.7326/0003-4819-151-4-200908180-00135. View

19.

Ruiz-Antoran B, Sancho-Lopez A, Torres F, Moreno-Torres V, de Pablo-Lopez I, Garcia-Lopez P . Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study. Infect Dis Ther. 2020; 10(1):347-362. PMC: 7719057. DOI: 10.1007/s40121-020-00373-8. View

20.

Ntaios G . Embolic Stroke of Undetermined Source: JACC Review Topic of the Week. J Am Coll Cardiol. 2020; 75(3):333-340. DOI: 10.1016/j.jacc.2019.11.024. View